Skip to main content

Table 1 Patients' characteristics.

From: Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells

patient sex age diagnosis Karyotype
mol biol
therapy* response§ relapse OS§§
   Ph- B-ALL
   #01 M 22 B common normal 1 + 2 CR Yes 29+
   #02 M 40 Pre-B NA 1 + 2 CR No 24+
   #03 M 16 B common normal 1 CR Yes 12
   #04 M 45 Pre-B normal 1 + 2 CR No 38+
   #05 F 53 B common hyperdiploid 1 CR No 71+
   #06 F 48 Pro-B t(4;11) 1 CR Yes 8
   #07 F 42 Pro-B t(4;11) 1 CR Yes 6
   #08 M 41 Pre-B t(6;8) 1 CR Yes 19
   #09 M 59 Pro-B t(4;11) 1 CR Yes 10
   #10 F 19 B common hyperdiploid 1 CR No 55+
   #11 M 17 B common t(17;22) 3 CR No 9+
   #12 F 53 B common NA 1 CR Yes 13+
   #13 F 43 B common normal 1 + 2 CR Yes 25
   #14 F 17 B common normal 3 NR Yes 4
   Ph+ B-ALL
   #01 M 44 Pre-B Ph masked
p210 (Y253H)
IM + D + 2 CR No 12+
   #02 F 54 B common t(9;22)
p210
1 (pre-IM) no CR   36
   #03 M 64 Pre-B t(9;22)
p210
IM CHR, CCyR Yes 9
   #04 M 19 B common t(9;22)
NA (E255V)
1 + IM + N no CHR   16
   #05 M 40 Pre-B t(9;22),-10
p210
1 + IM + D CHR, CCyR Yes 15
   #06 F 38 Pre-B t(9;22)
p190 (T315I)
1 + IM + D no CHR   9
   #07 M 17 B common t(9;22)
p210
1 (pre-IM) + 2 CR Yes 11
   #08 M 70 Pre-B t(9;22)
NA
5 (pre-IM) no CR   1
   #09 M 35 B common t(9;22), del(6)
p190
1 + IM + 2 CCyR, MMR No 46+
   #10 M 63 B common t(9;22)
p190
IM + CS CCyR, MMR No 15+
   #11 F 75 B common hyperdiploid, t(9;22), NA 5 (pre-IM) no CR   14
   #12 M 89 Pre-B t(9;22)
p190
IM CCyR, MMR Yes 22+
   #13 F 27 B common t(9;22)
p190
1 + IM no CHR   10
   #14 M 28 B common t(9;22)
p190
1 + IM + 2 CR Yes 37
   AML
   #01 M 59 M2 +4,+8 4 PR Yes 7
   #02 M 46 M0 NA 4 TD   1
   #03 F 37 M4 del(X)(p21) 4 CR No 167+
   #04 F 47 M2 normal 4 NR Yes 20
   #05 F 70 M4 Eo inv(16) 4 NR no CR 6
   #06 M 74 M4 normal 5    2
   #07 M 62 M4 normal 4 NR no CR 5
   #08 M 69 M4 Eo NA 5    5
   #09 M 60 M2 -7 4 CR No 38+
   #10 M 83 M2 NA 5    3
   #11 M 88 M2 NA 5    1
   #12 F 79 M0 normal 5    9
   #13 M 52 M4 normal 4 CR No 24+
   #14 F 61 M2 t(11;22) 4 CR Yes 11
  1. *Therapy: 1 = ALLVR589 protocol [10] or subsequent GIMEMA protocol LAL0496 [11]; 2 = allogeneic bone marrow transplantation; 3 = AIEOP-BFM-ALL 2000 protocol [12]; 4 = AML standard treatment (see Matherials and Methods); 5 = supportive care (hydroxicarbamide, blood transfusions etc); CS = corticosteroid; IM = imatinib; D = dasatinib; N = nilotinib
  2. §NA = not avalaible; CR = complete remission; PR = partial remission; NR = non-responder; TD = toxic death; CHR = complete hematologic remission; CCyR = complete cytogenetic remission; MMR = major molecular remission (>3 log reduction bcr/abl ratio)
  3. §§+ = ongoing follow-up